The Latest

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is on the upswing. Track the latest deals here.

    Incyte will pay $750 million to buy Escient Pharmaceuticals and its pipeline of small molecule drugs for inflammatory conditions like chronic urticaria.

    Updated 3 hours ago
  • Woman in bed with phone, headache.
    Image attribution tooltip

    shutterstock.com/ALDECA studio

    Image attribution tooltip
    Sponsored by Phreesia

    How can pharma speed time to treatment? Digital tools can help

    Treatment delays can seriously impact patients’ health outcomes. But by leveraging digital tools, pharma can help them find and access specialist care early in their journey.

  • The front entrance of the Food And Drug Administration headquarters building.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA rejects Abeona cell therapy, asks for more manufacturing data

    The complete response letter for Abeona’s treatment is one of several manufacturing setbacks for cell and gene therapy developers in recent years.

    FDA
  • A U.S. flag flying above a building showing a sign with the word Lilly written in red.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Lilly to buy injectable drug plant in manufacturing ramp-up

    The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.

  • An illustration of immune system T cells attacking cancer cells.
    Image attribution tooltip
    Meletios Verras via Getty Images
    Image attribution tooltip

    Bristol Myers taps startup to boost cell therapy production

    A partnership with Cellares, worth up to $380 million, is meant to help Bristol Myers speed and scale manufacture of CAR-T treatments for cancer.

  • Photo of Takeda Pharmaceutical's global headquarters in Japan.
    Image attribution tooltip
    Courtesy of Takeda Pharmaceuticals
    Image attribution tooltip

    Pharmas form joint venture to jumpstart Japanese drug research

    A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Cancer drug startup Lirum Pharmaceuticals set terms for what could be the 11th IPO so far this year. But it would also be one of the smallest, with about $25 million in anticipated proceeds.

    Updated April 19, 2024
  • A scientific illustration of amyloid plaques and neurons, colored in blue and orange.
    Image attribution tooltip
    selvanegra via Getty Images
    Image attribution tooltip

    Eisai hunts for next Alzheimer’s drug with new research pact

    A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.

  • An Ipsen site in Wrexham, UK.
    Image attribution tooltip
    Courtesy of Ipsen
    Image attribution tooltip

    Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

    The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA. 

  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical
    Image attribution tooltip

    Alvotech deal could heighten biosimilar pressure on Humira

    The agreement may help Alvotech capitalize on a recent policy shift by CVS that has driven major market share declines for AbbVie’s blockbuster drug.

  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche wins FDA OK for Alecensa in early lung cancer

    Alecensa is the first targeted drug available after surgery for people with ALK-positive lung tumors, who are at high risk for brain metastases.

    FDA
  • A person sits in an office chair next to a sign reading Cerevel.
    Image attribution tooltip
    Permission granted by Cerevel Therapeutics
    Image attribution tooltip

    Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study

    Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.

  • An injection pen containing the drug semaglutide lies on a white plate.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip
    Emerging biotech

    Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

    It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company acquired a portfolio of medicines it aims to test in combination.

  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex begins bid for US approval of non-opioid painkiller

    The biotech has begun a rolling submission of a closely watched drug that’s important to its future, but faces questions of sales potential.

    FDA
  • Anne Wojcicki speaking event
    Image attribution tooltip
    Brad Barket via Getty Images
    Image attribution tooltip

    23andMe CEO plans to take company private

    Company head Anne Wojcicki is considering buying all outstanding shares of the DNA testing firm, which has seen its stock slump in recent years.

  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly obesity drug shows benefit in sleep disorder study, pointing to new use

    Positive data for Lilly’s medicine tirzepatide in sleep apnea are the latest signal the benefits of GLP-1 agonists could extend beyond diabetes and weight loss.

  • An illustration of two neurons, colored blue and purple
    Image attribution tooltip
    noparrit via Getty Images
    Image attribution tooltip

    Sage’s cognition drug fails in Parkinson’s study

    Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.

  • A building showing a logo of Teva Pharmaceutical
    Image attribution tooltip
    Courtesy of Teva Pharmaceutical
    Image attribution tooltip

    Stelara biosimilar from Alvotech, Teva approved by FDA

    The companies plan to launch their copycat version of the blockbuster immune disease drug early next year, per a legal settlement with J&J.

  • Damaged hospital Ukraine
    Image attribution tooltip
    Chris McGrath via Getty Images
    Image attribution tooltip

    Ukraine was pharma’s clinical trial ‘darling.’ As war drags on, will the industry return?

    While some new drug studies are getting underway, activity is still far below bustling pre-war levels.

  • A portrait of Uwe Schoenbeck at Canaan Partners.
    Image attribution tooltip
    Permission granted by Canaan
    Image attribution tooltip

    Canaan hires Pfizer executive, reels in $100M for biotech investing

    The firm has brought in as venture partner Uwe Schoenbeck, who most recently was the top scientist for Pfizer’s emerging science and innovation unit.

  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J sees mixed performance from new multiple myeloma drugs

    Tecvayli sales, which J&J broke out for the first time, surpassed Wall Street forecasts and offset underperformance from Carvykti, which J&J attributed to the "phasing and timing of orders."

  • An illustration of a brain disintegrating
    Image attribution tooltip
    Eoneren via Getty Images
    Image attribution tooltip

    Intra-Cellular builds case for depression drug with late-stage trial win

    Shares of the biotech rose 25% after a large trial found adding its drug Caplyta onto antidepressant therapy significantly helped people with major depression.

  • An illustration of antibodies attacking a nerve cell.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Cullinan changes name, pivots to autoimmune disease

    The biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other inflammatory conditions.

  • Image attribution tooltip
    Regeneron
    Image attribution tooltip

    Regeneron commits $500M to new venture capital fund

    While corporate venture arms are commonplace among pharmaceutical companies, the new fund announced Monday is Regeneron’s first.

  • Neumora CEO Henry Gosebruch stands for a photo against a blurred office background
    Image attribution tooltip
    Permission granted by Neumora Therapeutics
    Image attribution tooltip

    Neumora’s schizophrenia drug hit with clinical hold

    Shares of the biotech dipped by double digits following disclosure the FDA had paused an early-stage study of Neumora’s muscarinic-targeting drug.

  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Roche reports survival data for new dual-acting lymphoma drug

    The results could give Roche’s Columvi an edge over a rival medicine from AbbVie and Genmab, while Regeneron awaits an approval of its own therapy.